Pharmaceutical

Regeneron and Mammoth team up to develop gene editing therapies

Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.

Apr 27, 2024 - 00:00
Regeneron and Mammoth team up to develop gene editing therapies
Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.
Read the original article

Tags:

Previous Article

Multiply Labs and GenScript partner on cell isolation automation

Next Article

AstraZeneca posts $2.18bn profit after tax in Q1 2024

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Invisible in the data: Broad ‘Asian American’ category obscures health disparities

Invisible in the data: Broad ‘Asian American’ category ...

Nov 21, 2023

How the political right came to back psychedelics to treat trauma

How the political right came to back psychedelics to tr...

Jul 8, 2023

‘There’s a huge fatphobia problem in the eating disorder world’: Even in treatment, weight stigma fails patients

‘There’s a huge fatphobia problem in the eating disorde...

Apr 25, 2023